R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Management of Low-Grade Gliomas
Riccardo Soffietti,Brigitta G. Baumert,Lorenzo Bello,A. von Deimling,Hugues Duffau,Marc Frenay,Wolfgang Grisold,Robin Grant,Francesc Graus,Khê Hoang-Xuan,Martin Klein,Beatrice Melin,Jeremy Rees,Tali Siegal,Anja Smits,Roger Stupp,Wolfgang Wick +16 more
TL;DR: The objective is to avoid malignant transformation as long as possible while preserving the quality of life, since this tumour mostly occurs in young patients having a family life and a regular social and professional activity.
Journal ArticleDOI
The Lugano International Conferences on Malignant Lymphoma, 1981-1993
Proceedings ArticleDOI
Abstract 1504: Tumor-treating fields (TTFields) interfere with biological key properties of glioma cells in vitro
TL;DR: It is demonstrated that the application of TTFields may interfere with various biological key properties of glioma cells and may allow for a more detailed clinical evaluation of T TFields beyond the clinical data available so far.
Journal ArticleDOI
Accelerated postoperative radiation therapy with weekly concomitant boost in patients with advanced head and neck cancer.
Abderrahim Zouhair,David Azria,Philippe Pasche,Philippe Coucke,Roger Stupp,Julia Chevalier,R.O. Mirimanoff,Mahmut Ozsahin +7 more
TL;DR: Reducing the overall treatment time using postoperative accelerated RT by weekly concomitant boost (6 fractions per week) is easily feasible with excellent local control and adjuvant chemotherapy should be considered.
Journal ArticleDOI
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
Marijke B. Coomans,Linda Dirven,Neil K. Aaronson,Brigitta G. Baumert,Martin J. van den Bent,Andrew Bottomley,A. A. Brandes,Olivier Chinot,Corneel Coens,Thierry Gorlia,Ulrich Herrlinger,Florence Keime-Guibert,Annika Malmström,Francesca Martinelli,Jeff A. Sloan,Roger Stupp,Andrea Talacchi,Michael Weller,Wolfgang Wick,Jaap C. Reijneveld,Martin J B Taphoorn +20 more
TL;DR: Both methods combining survival and health-related quality of life data in glioma trials to calculate the net clinical benefit resulted in different outcomes, but adjusting for the impact of treatment on HRQoL resulted in theoretically reduced survival benefits.